Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty

Aurora Zanghì, Anneke van der Walt, Emanuele D’Amico

Open source

DOI
10.3389/fimmu.2026.1917676
Published
2026-10-22
Container
Frontiers in Immunology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1917676,
  title = {Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty},
  author = {Aurora Zanghì and Anneke van der Walt and Emanuele D’Amico},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1917676},
  url = {https://doi.org/10.3389/fimmu.2026.1917676}
}

RIS

TY  - JOUR
TI  - Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty
AU  - Aurora Zanghì
AU  - Anneke van der Walt
AU  - Emanuele D’Amico
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1917676
UR  - https://doi.org/10.3389/fimmu.2026.1917676
ER  - 

APA

Zanghì, A., Walt, A. V. D., & D’Amico, E. (2026). Is it time for anti-CD20 discontinuation in multiple sclerosis? Cumulative risk or cumulative uncertainty. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1917676

Source records